Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 10 | 2022 | 32 | 1.830 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2022 | 206 | 1.530 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2019 | 66 | 1.260 |
Why?
|
| Rheumatic Diseases | 3 | 2017 | 20 | 1.110 |
Why?
|
| Antirheumatic Agents | 6 | 2021 | 54 | 1.000 |
Why?
|
| Granulomatosis with Polyangiitis | 2 | 2021 | 9 | 0.950 |
Why?
|
| Rheumatology | 3 | 2022 | 28 | 0.830 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2021 | 19 | 0.800 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 27 | 0.710 |
Why?
|
| Catatonia | 1 | 2019 | 8 | 0.690 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2019 | 8 | 0.680 |
Why?
|
| Electroconvulsive Therapy | 1 | 2019 | 24 | 0.670 |
Why?
|
| Aspirin | 1 | 2019 | 156 | 0.650 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 243 | 0.650 |
Why?
|
| Immunologic Factors | 1 | 2019 | 170 | 0.640 |
Why?
|
| Macrophage Activation Syndrome | 1 | 2015 | 2 | 0.540 |
Why?
|
| Antibodies, Antinuclear | 1 | 2015 | 83 | 0.520 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 316 | 0.500 |
Why?
|
| Child | 23 | 2022 | 6928 | 0.460 |
Why?
|
| Adolescent | 17 | 2022 | 8982 | 0.420 |
Why?
|
| Immunosuppressive Agents | 5 | 2019 | 977 | 0.420 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 2 | 2022 | 7 | 0.370 |
Why?
|
| Microscopic Polyangiitis | 2 | 2022 | 2 | 0.370 |
Why?
|
| Glucocorticoids | 3 | 2018 | 352 | 0.350 |
Why?
|
| Lupus Nephritis | 3 | 2018 | 78 | 0.270 |
Why?
|
| Female | 24 | 2023 | 44534 | 0.270 |
Why?
|
| Arthralgia | 2 | 2015 | 36 | 0.260 |
Why?
|
| Humans | 35 | 2023 | 86645 | 0.260 |
Why?
|
| Mycophenolic Acid | 3 | 2022 | 87 | 0.250 |
Why?
|
| Atherosclerosis | 3 | 2013 | 244 | 0.240 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 67 | 0.220 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.220 |
Why?
|
| Heptanoic Acids | 2 | 2013 | 72 | 0.210 |
Why?
|
| Cyclophosphamide | 3 | 2018 | 299 | 0.210 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2002 | 73 | 0.210 |
Why?
|
| Skin Ulcer | 1 | 2021 | 25 | 0.200 |
Why?
|
| Pyrroles | 2 | 2013 | 184 | 0.200 |
Why?
|
| Pediatrics | 3 | 2017 | 344 | 0.200 |
Why?
|
| Abatacept | 1 | 2021 | 83 | 0.190 |
Why?
|
| Withholding Treatment | 2 | 2019 | 112 | 0.190 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 50 | 0.190 |
Why?
|
| DNA, Viral | 1 | 2001 | 265 | 0.180 |
Why?
|
| Saliva | 1 | 2001 | 122 | 0.180 |
Why?
|
| Drug Therapy, Combination | 3 | 2018 | 894 | 0.170 |
Why?
|
| S100A12 Protein | 1 | 2019 | 10 | 0.170 |
Why?
|
| Calgranulin A | 1 | 2019 | 11 | 0.170 |
Why?
|
| Calgranulin B | 1 | 2019 | 16 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2021 | 7993 | 0.170 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 2 | 2009 | 7 | 0.170 |
Why?
|
| Benzodiazepines | 1 | 2019 | 65 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 2357 | 0.160 |
Why?
|
| Methotrexate | 4 | 2021 | 249 | 0.160 |
Why?
|
| Infant | 3 | 2019 | 3047 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 147 | 0.150 |
Why?
|
| Prednisone | 3 | 2015 | 258 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2018 | 223 | 0.150 |
Why?
|
| Nephrotic Syndrome | 1 | 2016 | 33 | 0.140 |
Why?
|
| Male | 17 | 2023 | 40967 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2011 | 2271 | 0.140 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2015 | 11 | 0.130 |
Why?
|
| Child, Preschool | 6 | 2019 | 3613 | 0.130 |
Why?
|
| Remission Induction | 2 | 2018 | 722 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 190 | 0.130 |
Why?
|
| Respiratory Insufficiency | 1 | 2016 | 150 | 0.130 |
Why?
|
| Calcitonin | 1 | 2014 | 38 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2016 | 268 | 0.120 |
Why?
|
| Cyclosporine | 1 | 2015 | 234 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2014 | 36 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2016 | 263 | 0.120 |
Why?
|
| Knee Joint | 1 | 2015 | 168 | 0.120 |
Why?
|
| Bone Density | 1 | 2014 | 209 | 0.110 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 47 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2014 | 121 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 508 | 0.110 |
Why?
|
| Biomarkers | 3 | 2019 | 1718 | 0.110 |
Why?
|
| Vitamin D | 1 | 2014 | 261 | 0.100 |
Why?
|
| Risk Factors | 7 | 2023 | 5417 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 582 | 0.100 |
Why?
|
| Intracranial Aneurysm | 1 | 2013 | 158 | 0.100 |
Why?
|
| Disease Progression | 4 | 2023 | 1531 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 509 | 0.100 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 81 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 95 | 0.100 |
Why?
|
| Anticholesteremic Agents | 1 | 2012 | 137 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 2 | 2022 | 21 | 0.090 |
Why?
|
| STAT4 Transcription Factor | 1 | 2009 | 10 | 0.090 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 29 | 0.090 |
Why?
|
| Tunica Intima | 1 | 2009 | 59 | 0.080 |
Why?
|
| Symptom Flare Up | 2 | 2019 | 11 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 378 | 0.080 |
Why?
|
| Selenoprotein P | 1 | 2007 | 1 | 0.080 |
Why?
|
| Musculoskeletal Diseases | 1 | 2008 | 34 | 0.080 |
Why?
|
| Models, Molecular | 1 | 2011 | 1286 | 0.080 |
Why?
|
| Prospective Studies | 4 | 2018 | 4213 | 0.070 |
Why?
|
| Registries | 3 | 2018 | 703 | 0.070 |
Why?
|
| Proteoglycans | 1 | 1986 | 121 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 689 | 0.070 |
Why?
|
| Neutrophils | 1 | 1986 | 307 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 683 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1351 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2018 | 2767 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 827 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2013 | 1823 | 0.060 |
Why?
|
| Azathioprine | 2 | 2016 | 125 | 0.060 |
Why?
|
| Young Adult | 4 | 2022 | 5976 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2216 | 0.050 |
Why?
|
| Carotid Intima-Media Thickness | 2 | 2013 | 38 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2003 | 136 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2898 | 0.050 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2000 | 18 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2001 | 36 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2022 | 129 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 5210 | 0.050 |
Why?
|
| Health Status | 1 | 2003 | 360 | 0.050 |
Why?
|
| Sex Factors | 2 | 2017 | 1054 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 1585 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2023 | 711 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2016 | 263 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 293 | 0.040 |
Why?
|
| Life Tables | 1 | 2018 | 48 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2001 | 927 | 0.040 |
Why?
|
| Sulfonamides | 1 | 2000 | 300 | 0.040 |
Why?
|
| Echocardiography | 1 | 2023 | 911 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 1565 | 0.040 |
Why?
|
| Rheumatologists | 1 | 2017 | 6 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 839 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2501 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1621 | 0.040 |
Why?
|
| United States | 3 | 2016 | 6674 | 0.040 |
Why?
|
| Consensus | 1 | 2018 | 335 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2016 | 26 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2009 | 361 | 0.040 |
Why?
|
| Haplotypes | 2 | 2009 | 642 | 0.040 |
Why?
|
| Asia | 1 | 2016 | 95 | 0.040 |
Why?
|
| Health Surveys | 1 | 2017 | 239 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2018 | 751 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2016 | 60 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2017 | 162 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 204 | 0.030 |
Why?
|
| Rituximab | 1 | 2016 | 116 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 204 | 0.030 |
Why?
|
| Proteinuria | 1 | 2016 | 107 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 859 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 309 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 1851 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 45 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 99 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 943 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 278 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2016 | 355 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 154 | 0.030 |
Why?
|
| Puberty | 1 | 2013 | 59 | 0.030 |
Why?
|
| Incidence | 1 | 2017 | 1577 | 0.030 |
Why?
|
| Kidney | 1 | 2018 | 1241 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2013 | 293 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 2011 | 10 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2011 | 48 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2013 | 127 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2013 | 222 | 0.030 |
Why?
|
| California | 1 | 2011 | 138 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 155 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 287 | 0.020 |
Why?
|
| Lipoprotein(a) | 1 | 2010 | 28 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 813 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2010 | 83 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 276 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 218 | 0.020 |
Why?
|
| Lipoproteins, HDL | 1 | 2010 | 96 | 0.020 |
Why?
|
| Lipids | 1 | 2012 | 269 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3640 | 0.020 |
Why?
|
| Triglycerides | 1 | 2010 | 232 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 8491 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2009 | 52 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 480 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2009 | 135 | 0.020 |
Why?
|
| Cholesterol | 1 | 2010 | 356 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 310 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2007 | 3 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 338 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1456 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2062 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2009 | 267 | 0.020 |
Why?
|
| Zymosan | 1 | 1986 | 6 | 0.020 |
Why?
|
| Chondroitinases and Chondroitin Lyases | 1 | 1986 | 8 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3030 | 0.020 |
Why?
|
| Glycosides | 1 | 1986 | 20 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1986 | 81 | 0.020 |
Why?
|
| Sulfates | 1 | 1986 | 56 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 695 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2007 | 473 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2009 | 770 | 0.020 |
Why?
|
| Leukocytes | 1 | 1986 | 202 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 1540 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2009 | 1805 | 0.020 |
Why?
|
| Computational Biology | 1 | 2007 | 528 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 1986 | 263 | 0.010 |
Why?
|
| Joints | 1 | 2003 | 32 | 0.010 |
Why?
|
| Injections, Intra-Articular | 1 | 2003 | 27 | 0.010 |
Why?
|
| Uveitis | 1 | 2003 | 29 | 0.010 |
Why?
|
| Phenotype | 1 | 2009 | 2378 | 0.010 |
Why?
|
| Educational Status | 1 | 2003 | 188 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 204 | 0.010 |
Why?
|
| Adult | 1 | 2001 | 25648 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1621 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1986 | 2818 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 37 | 0.010 |
Why?
|
| Celecoxib | 1 | 2000 | 31 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 100 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2000 | 271 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2000 | 153 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 1801 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 11352 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 1196 | 0.010 |
Why?
|
| Arthrography | 1 | 1993 | 6 | 0.010 |
Why?
|
| Carpal Bones | 1 | 1993 | 12 | 0.010 |
Why?
|
| Wrist Joint | 1 | 1993 | 23 | 0.010 |
Why?
|
| Movement | 1 | 1993 | 299 | 0.010 |
Why?
|
| Animals | 1 | 2009 | 26582 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 159 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1989 | 429 | 0.010 |
Why?
|